Due to loss of patent for major brands in the late-stage chronic kidney disease (CKD) market, and the changing reimbursement environment across the six major markets (6MM), the CKD sales revenue is forecasted to decrease at a negative CAGR of 2.5% between 2012 and 2017. The late-stage CKD therapeutics market in the 6MM (US, France, Germany, Italy, Spain, and UK) will decline from USD 1.88 billion in 2012 to USD 1.66 billion by 2017. It is expected that the majority of sales in the will still come from the US (76%), with marginal increase in the 5EU’s share (24%) during 2012 to 2017.
Visit : http://www.researchonglobalmarkets.com/opportunityanalyzer-late-stage-chronic-kidney-disease-ckd-opportunity-analysis-and-forecasts-to-2017.html
